- Organizations: Tenpoint Therapeutics
Products
FDA approves Tenpoint's YUVEZZI as first dual-agent presbyopia drop
First and only combination drop of carbachol and brimonidine tartrate achieves miosis within 30 minutes and lasts up to 10 hours following once-daily dosing.
Pipeline
FDA accepts Tenpoint's Brimochol PF NDA for presbyopia
Fixed-dose-combo eye drop of brimonidine tartrate and carbachol has demonstrated a statistically significant reduction in pupil size up to 10 hours; PDUFA date set for January.Pipeline
Tenpoint submits NDA for Brimochol PF for presbyopia
The FDA begins a 60-day review period to determine if the submission for the pupil-modulating eye drop is acceptable.
Business
Tenpoint Therapeutics names veteran executive as first CCO
Carol Kearney to lead company’s efforts to launch and expand global availability of BRIMOCHOL PF for presbyopia.Pipeline
Tenpoint reports positive topline data from phase 3 presbyopia eye drop study
With BRIMOCHOL PF meeting its prespecified primary endpoints, the company is planning for a regulatory filing within the first half of 2025.
Business
Tenpoint and Visus Therapeutics merge with plans for ophthalmic therapeutic advancements
Newly-combined Tenpoint Therapeutics, Ltd includes a pipeline featuring BRIMOCHOL PF, a once-daily eye drop for presbyopia targeting an NDA filing in 2025.
Research